Our data suggest that inhibiting S1P signaling may be a beneficial therapeutic modality in the treatment of MCL because the blockade of S1P signaling could both inhibit proliferation of MCL and restore NKT cell mediated cytotoxic responses to MCL. This evidence concerns the gene MBTPS1 and mantle cell lymphoma.